Abbott launches HBsAg Next Assay for enhanced detection of Hepatitis B

Assay to help detect HBV infections and mutants at an earlier stage even in vaccinated individuals

Abbott has announced the launch of the HBsAg Next Qualitative solution in India to enhance detection of the Hepatitis B virus (HBV). This assay will help improve patient outcomes while maintaining safe blood supplies. This highly sensitive chemiluminescent microparticle immunoassay (CMIA) assists in the early and enhanced detection of HBV in human serum and plasma (blood) samples and in population screening. A chemiluminescent immunoassay is a variation of the standard enzyme immunoassay, a biochemical technique used in immunology.

It detects HBV surface antigen (HBsAg) in human serum and plasma. Moreover, it overcomes traditional challenges by showcasing the highest level of assay performance required to detect infection in immunocompromised groups.

Dr Jaganathan Sickan, Senior Associate Director, Medical Affairs, Core Diagnostics, Abbott said, “In India, Hepatitis B screening is vital since it is vastly under diagnosed. With HBsAg Next qualitative assay, laboratories in India can now detect HBV earlier than ever. This will help physicians identify at risk patients sooner, which in turn leads to early treatment and care. This assay represents the next generation of HBV diagnostic performance and will enhance our comprehensive infectious disease portfolio.”




Abbott DiagnosticsHepatitis BLiver diseases
Comments (0)
Add Comment